SPRO News and Press, Spero Therapeutics Inc. From 03/13/24

2024-03-13 17:45:09 ET Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Conference Call March 13, 2024, 04:30 PM ET Company Participants Michael Wood - Managing Director of LifeSci Advisors Sath Shukla - CEO Kamal Hamed - CMO Esther Rajavelu - CFO and Chief B...

2024-03-13 16:18:52 ET More on Spero Therapeutics Spero Therapeutics Q4 2023 Earnings Preview Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings d...

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI Submitted IND f...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

2024-03-12 17:35:56 ET More on Spero Therapeutics Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings data for Spero Therapeutics Financial informa...

2024-03-12 17:35:31 ET Major earnings expected after the bell on Wednesday include: UiPath ( PATH ) SentinelOne ( S ) Lennar Corporation ( LEN ) GrowGeneration Corp. ( GRWG ) Limbach Holdings ( LMB ) Read the full article on Seeking Alpha ...

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial inf...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacteria...

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today anno...

2024-01-05 08:19:04 ET More on Spero Therapeutics Spero Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings data for Spero Therapeutics Financial information for Spero Therapeutics For fu...